EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease

Cristina Parrado Fernandez, Sanja Juric, Maria Backlund, Märta Dahlström, Nather Madjid, Veronica Lidell, Azita Rasti, Johan Sandin iD, Gunnar Nordvall iD, Pontus Forsell iD

International Journal of Molecular Sciences · 06.07.2023 · 24 (13) · 11159

DOI: 10.3390/ijms241311159 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 06.07.2023. Verfasst von Cristina Parrado Fernandez und 9 weiteren Autor:innen. Beteiligte Einrichtung: AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden. Hauptthemen laut MEDLINE: Alzheimer Disease, Neuroblastoma, Neuroprotective Agents, Cognitive Dysfunction. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The introduction of anti-amyloid monoclonal antibodies against Alzheimer’s disease (AD) is of high importance. However, even though treated patients show very little amyloid pathology, there is only a modest effect on the rate of cognitive decline. Although this effect can possibly increase over time, there is still a need for alternative treatments that will improve cognitive function in patients with AD. Therefore, the purpose of this study was to characterize the triazinetrione ACD856, a novel pan-Trk positive allosteric modulator, in multiple models to address its neuroprotective and potential disease-modifying effects. The pharmacological effect of ACD856 was tested in recombinant cell lines, primary cortical neurons, or animals. We demonstrate that ACD856 enhanced NGF-induced neurite outgrowth, increased the levels of the pre-synaptic protein SNAP25 in PC12 cells, and increased the degree of phosphorylated TrkB in SH-SY5Y cells. In primary cortical neurons, ACD856 led to increased levels of phospho-ERK1/2, showed a neuroprotective effect against amyloid-beta or energy-deprivation-induced neurotoxicity, and increased the levels of brain-derived neurotrophic factor (BDNF). Consequently, administration of ACD856 resulted in a significant increase in BDNF in the brains of 21 months old mice. Furthermore, repeated administration of ACD856 resulted in a sustained anti-depressant effect, which lasted up to seven days, suggesting effects that go beyond merely symptomatic effects. In conclusion, the results confirm ACD856 as a cognitive enhancer, but more importantly, they provide substantial in vitro and in vivo evidence of neuroprotective and long-term effects that contribute to neurotrophic support and increased neuroplasticity. Presumably, the described effects of ACD856 may improve cognition, increase resilience, and promote neurorestorative processes, thereby leading to a healthier brain in patients with AD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseNeuroblastomaNeuroprotective AgentsCognitive DysfunctionRatsMiceHumansAnimalsBrain-Derived Neurotrophic FactorAmyloid beta-PeptidesPC12 Cells

Stichwörter der Autor:innen

Alzheimer’s diseaseallosteric modulatoranti-depressantbrain-derived neurotrophic factorcognitive functionnerve growth factor

Substanzen

Brain-Derived Neurotrophic FactorAmyloid beta-PeptidesNeuroprotective Agents

Autor:innen und Institutionen

  • AlzeCure Pharma AB, Hälsovägen 7, 141 57 Huddinge, Sweden.
  • Division of Neuroscience, Care and Society, Department of Neurogeriatrics, Karolinska Institutet, 171 77 Solna, Sweden.

ORCID-Profile: Johan Sandin, Gunnar Nordvall, Pontus Forsell

Zitieren

APA

Parrado Fernandez, C., Juric, S., Backlund, M., Dahlström, M., Madjid, N., Lidell, V., Rasti, A., Sandin, J., Nordvall, G., & Forsell, P. (2023). Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences, 24(13), 11159. https://doi.org/10.3390/ijms241311159

Vancouver

Parrado Fernandez C, Juric S, Backlund M, Dahlström M, Madjid N, Lidell V, et al. Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease. International Journal of Molecular Sciences. 2023;24(13):11159. doi:10.3390/ijms241311159

BibTeX
@article{ParradoFernandez2023,
  author = {Parrado Fernandez, Cristina and Juric, Sanja and Backlund, Maria and Dahlström, Märta and Madjid, Nather and Lidell, Veronica and Rasti, Azita and Sandin, Johan and Nordvall, Gunnar and Forsell, Pontus},
  title = {Neuroprotective and Disease-Modifying Effects of the Triazinetrione ACD856, a Positive Allosteric Modulator of Trk-Receptors for the Treatment of Cognitive Dysfunction in Alzheimer’s Disease},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  volume = {24},
  number = {13},
  pages = {11159},
  doi = {10.3390/ijms241311159}
}
Kostenlos starten →